Contact

Esketamine Use and Attempted Suicide or Intentional Self-Harm Among Individuals with Treatment-Resistant Depression: A Retrospective Cohort Study

Wang Y, Storaci AS, Alexander GC, Gibbons JB - Drug Safety

  • Research Publications
| September 2026
  • Regulation and Clinical Evidence

Summary:

Among over 23,000 adults with treatment-resistant depression (TRD) in a national claims database, esketamine (Spravato) use was not associated with a statistically distinguishable difference in nonfatal, medically attended suicide attempts or intentional self-harm.

VIEW SOURCE
Simple graphic of magnifying glass examining papers to signify reviewing research publications.

LEARN MORE

BROWSE RESEARCH PUBLICATIONS

Recent Work from PORTAL

Talk bubble graphics representing commentary and opinion.

How Congress Can Fix Expert Advisory Committees

Daval CJR, Kesselheim AS - STAT

  • Commentary & Opinion
| October 2026
  • Regulation and Clinical Evidence
View Source
Simple graphic of magnifying glass examining papers to signify reviewing research publications.

International Regulatory Status and Reimbursement Recommendations of Haematological Malignancy Drugs Withdrawn from the FDA Accelerated Approval Pathway

Mulsant SS, Kesselheim AS, Naci H - Journal of Cancer Policy

  • Research Publications
| October 2026
  • Price, Value, and Access
  • Regulation and Clinical Evidence
View Source
Talk bubble graphics representing commentary and opinion.

Politics and the Patient Encounter, in Dire Times

Avorn J - MedPage Today

  • Commentary & Opinion
| October 2026
  • Regulation and Clinical Evidence
View Source
VIEW MORE

Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital • Harvard Medical School
41 Avenue Louis Pasteur, Suite 0B17, Boston, MA 02115

©2026 Program On Regulation, Therapeutics, And Law (PORTAL). All rights reserved.